Compare Crispr Therapeutics AG (CRSP) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Gold Fields Limited — how do they compare? Crispr Therapeutics AG trades at $50.1 (market cap $4.97B), while Gold Fields Limited trades at $32.32 (market cap $29.97B). The key difference: Gold Fields Limited is far larger — about 6× Crispr Therapeutics AG's market cap, and Gold Fields Limited pays a 6.96% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | GFI | |
|---|---|---|
Market Cap | $4.97B | $29.97B |
Sector | Health | Basic Materials |
52-Week High | $76.78 | $61.52 |
52-Week Low | $44.34 | $23.95 |
Enterprise Value | $3.32B | $31.41B |
Dividend Yield | — | 6.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Gold Fields (GFI) trades at $33.53, down 1.79% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with a P/E of 8.51, net income margin of 40.76%, and robust ROE of 52.33%. Recent earnings were mixed, with a Q1 2025 beat but subsequent misses. Cash flow improved significantly in 2025, and revenue growth accelerated to $8.8B. Analyst consensus is a Buy with a $52.75 price target, though recent news highlights operational cost pressures.
The outlook for GFI is positive based on valuation and profitability, but near-term risks include cost inflation and gold price volatility. The stock offers value with upside to analyst targets, supported by strong cash generation and a shareholder-friendly dividend policy. Key risks are execution at mines and macroeconomic factors affecting gold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
